Signal Peptide Website


Signal Peptide Database - Viruses

 Entry Details
ID   2824
Source Database   UniProtKB/Swiss-Prot
UniProtKB/Swiss-Prot Accession Number   Q6Q1S2    (Created: 2005-07-19 Updated: 2008-11-25)
UniProtKB/Swiss-Prot Entry Name   SPIKE_CVHNL
Protein Name   Spike glycoprotein
Gene   S
Organism Scientific   Human coronavirus NL63
Organism Common   HCoV-NL63
Lineage   Viruses
  ssRNA positive-strand viruses, no DNA stage
    Nidovirales
      Coronaviridae
        Coronavirus
          Coronavirus group 1
            Coronavirus group 1b
Protein Length [aa]   1356
Protein Mass [Da]   149850
Features  
TypeDescriptionStatusStartEnd
signal peptide      potential   1   15
chain   Spike glycoprotein      16   1356
transmembrane region      potential   1297   1317
topological domain   Extracellular   potential   14   1296
topological domain   Cytoplasmic   potential   1318   1356
region of interest   S1      16   717
region of interest   S2      718   1356
glycosylation site   N-linked (GlcNAc...)   potential   24   24
glycosylation site   N-linked (GlcNAc...)   potential   35   35
glycosylation site   N-linked (GlcNAc...)   potential   52   52
glycosylation site   N-linked (GlcNAc...)   potential   98   98
glycosylation site   N-linked (GlcNAc...)   potential   111   111
glycosylation site   N-linked (GlcNAc...)   potential   119   119
glycosylation site   N-linked (GlcNAc...)   potential   155   155
glycosylation site   N-linked (GlcNAc...)   potential   178   178
glycosylation site   N-linked (GlcNAc...)   potential   187   187
glycosylation site   N-linked (GlcNAc...)   potential   193   193
glycosylation site   N-linked (GlcNAc...)   potential   203   203
glycosylation site   N-linked (GlcNAc...)   potential   240   240
glycosylation site   N-linked (GlcNAc...)   potential   276   276
glycosylation site   N-linked (GlcNAc...)   potential   301   301
glycosylation site   N-linked (GlcNAc...)   potential   330   330
glycosylation site   N-linked (GlcNAc...)   potential   354   354
glycosylation site   N-linked (GlcNAc...)   potential   358   358
glycosylation site   N-linked (GlcNAc...)   potential   403   403
glycosylation site   N-linked (GlcNAc...)   potential   426   426
glycosylation site   N-linked (GlcNAc...)   potential   486   486
glycosylation site   N-linked (GlcNAc...)   potential   506   506
glycosylation site   N-linked (GlcNAc...)   potential   512   512
glycosylation site   N-linked (GlcNAc...)   potential   626   626
glycosylation site   N-linked (GlcNAc...)   potential   645   645
glycosylation site   N-linked (GlcNAc...)   potential   666   666
glycosylation site   N-linked (GlcNAc...)   potential   699   699
glycosylation site   N-linked (GlcNAc...)   potential   723   723
glycosylation site   N-linked (GlcNAc...)   potential   749   749
glycosylation site   N-linked (GlcNAc...)   potential   762   762
glycosylation site   N-linked (GlcNAc...)   potential   768   768
glycosylation site   N-linked (GlcNAc...)   potential   844   844
glycosylation site   N-linked (GlcNAc...)   potential   852   852
glycosylation site   N-linked (GlcNAc...)   potential   1111   1111
glycosylation site   N-linked (GlcNAc...)   potential   1196   1196
glycosylation site   N-linked (GlcNAc...)   potential   1201   1201
glycosylation site   N-linked (GlcNAc...)   potential   1218   1218
glycosylation site   N-linked (GlcNAc...)   potential   1242   1242
glycosylation site   N-linked (GlcNAc...)   potential   1247   1247
glycosylation site   N-linked (GlcNAc...)   potential   1277   1277
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03- 40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001)      0   0
sequence variant   (in strain: Isolate BE03-40001)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-1153, Isolate BE03-40001, Isolate BE03-64880, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-1153, Isolate BE03-64880)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-1153, Isolate BE03-64880, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      0   0
sequence variant   (in strain: Isolate BE03-40001, Isolate NL)      110   110
compositionally biased region   Cys-rich      1317   1340
short sequence motif   KxHxx   by similarity   1352   1356
coiled-coil region      potential   1015   1059
coiled-coil region      potential   1244   1286
SP Length   15
 ----+----1----+----2----+----3----+----4----+----5
Signal Peptide MKLFLILLVLPLASC
Sequence MKLFLILLVLPLASCFFTCNSNANLSMLQLGVPDNSSTIVTGLLPTHWFC
ANQSTSVYSANGFFYIDVGNHRSAFALHTGYYDANQYYIYVTNEIGLNAS
VTLKICKFSRNTTFDFLSNASSSFDCIVNLLFTEQLGAPLGITISGETVR
LHLYNVTRTFYVPAAYKLTKLSVKCYFNYSCVFSVVNATVTVNVTTHNGR
VVNYTVCDDCNGYTDNIFSVQQDGRIPNGFPFNNWFLLTNGSTLVDGVSR
LYQPLRLTCLWPVPGLKSSTGFVYFNATGSDVNCNGYQHNSVVDVMRYNL
NFSANSLDNLKSGVIVFKTLQYDVLFYCSNSSSGVLDTTIPFGPSSQPYY
CFINSTINTTHVSTFVGILPPTVREIVVARTGQFYINGFKYFDLGFIEAV
NFNVTTASATDFWTVAFATFVDVLVNVSATNIQNLLYCDSPFEKLQCEHL
QFGLQDGFYSANFLDDNVLPETYVALPIYYQHTDINFTATASFGGSCYVC
KPHQVNISLNGNTSVCVRTSHFSIRYIYNRVKSGSPGDSSWHIYLKSGTC
PFSFSKLNNFQKFKTICFSTVEVPGSCNFPLEATWHYTSYTIVGALYVTW
SEGNSITGVPYPVSGIREFSNLVLNNCTKYNIYDYVGTGIIRSSNQSLAG
GITYVSNSGNLLGFKNVSTGNIFIVTPCNQPDQVAVYQQSIIGAMTAVNE
SRYGLQNLLQLPNFYYVSNGGNNCTTAVMTYSNFGICADGSLIPVRPRNS
SDNGISAIITANLSIPSNWTTSVQVEYLQITSTPIVVDCATYVCNGNPRC
KNLLKQYTSACKTIEDALRLSAHLETNDVSSMLTFDSNAFSLANVTSFGD
YNLSSVLPQRNIRSSRIAGRSALEDLLFSKVVTSGLGTVDVDYKSCTKGL
SIADLACAQYYNGIMVLPGVADAERMAMYTGSLIGGMVLGGLTSAAAIPF
SLALQARLNYVALQTDVLQENQKILAASFNKAINNIVASFSSVNDAITQT
AEAIHTVTIALNKIQDVVNQQGSALNHLTSQLRHNFQAISNSIQAIYDRL
DSIQADQQVDRLITGRLAALNAFVSQVLNKYTEVRGSRRLAQQKINECVK
SQSNRYGFCGNGTHIFSIVNSAPDGLLFLHTVLLPTDYKNVKAWSGICVD
GIYGYVLRQPNLVLYSDNGVFRVTSRVMFQPRLPVLSDFVQIYNCNVTFV
NISRVELHTVIPDYVDVNKTLQEFAQNLPKYVKPNFDLTPFNLTYLNLSS
ELKQLEAKTASLFQTTVELQGLIDQINSTYVDLKLLNRFENYIKWPWWVW
LIISVVFVVLLSLLVFCCLSTGCCGCCNCLTSSMRGCCDCGSTKLPYYEF
EKVHVQ
Original MKLFLILLVLPLASCFFTCNSNANLSMLQLGVPDNSSTIVTGLLPTHWFC
ANQSTSVYSANGFFYIDVGNHRSAFALHTGYYDANQYYIYVTNEIGLNAS
VTLKICKFSRNTTFDFLSNASSSFDCIVNLLFTEQLGAPLGITISGETVR
LHLYNVTRTFYVPAAYKLTKLSVKCYFNYSCVFSVVNATVTVNVTTHNGR
VVNYTVCDDCNGYTDNIFSVQQDGRIPNGFPFNNWFLLTNGSTLVDGVSR
LYQPLRLTCLWPVPGLKSSTGFVYFNATGSDVNCNGYQHNSVVDVMRYNL
NFSANSLDNLKSGVIVFKTLQYDVLFYCSNSSSGVLDTTIPFGPSSQPYY
CFINSTINTTHVSTFVGILPPTVREIVVARTGQFYINGFKYFDLGFIEAV
NFNVTTASATDFWTVAFATFVDVLVNVSATNIQNLLYCDSPFEKLQCEHL
QFGLQDGFYSANFLDDNVLPETYVALPIYYQHTDINFTATASFGGSCYVC
KPHQVNISLNGNTSVCVRTSHFSIRYIYNRVKSGSPGDSSWHIYLKSGTC
PFSFSKLNNFQKFKTICFSTVEVPGSCNFPLEATWHYTSYTIVGALYVTW
SEGNSITGVPYPVSGIREFSNLVLNNCTKYNIYDYVGTGIIRSSNQSLAG
GITYVSNSGNLLGFKNVSTGNIFIVTPCNQPDQVAVYQQSIIGAMTAVNE
SRYGLQNLLQLPNFYYVSNGGNNCTTAVMTYSNFGICADGSLIPVRPRNS
SDNGISAIITANLSIPSNWTTSVQVEYLQITSTPIVVDCATYVCNGNPRC
KNLLKQYTSACKTIEDALRLSAHLETNDVSSMLTFDSNAFSLANVTSFGD
YNLSSVLPQRNIRSSRIAGRSALEDLLFSKVVTSGLGTVDVDYKSCTKGL
SIADLACAQYYNGIMVLPGVADAERMAMYTGSLIGGMVLGGLTSAAAIPF
SLALQARLNYVALQTDVLQENQKILAASFNKAINNIVASFSSVNDAITQT
AEAIHTVTIALNKIQDVVNQQGSALNHLTSQLRHNFQAISNSIQAIYDRL
DSIQADQQVDRLITGRLAALNAFVSQVLNKYTEVRGSRRLAQQKINECVK
SQSNRYGFCGNGTHIFSIVNSAPDGLLFLHTVLLPTDYKNVKAWSGICVD
GIYGYVLRQPNLVLYSDNGVFRVTSRVMFQPRLPVLSDFVQIYNCNVTFV
NISRVELHTVIPDYVDVNKTLQEFAQNLPKYVKPNFDLTPFNLTYLNLSS
ELKQLEAKTASLFQTTVELQGLIDQINSTYVDLKLLNRFENYIKWPWWVW
LIISVVFVVLLSLLVFCCLSTGCCGCCNCLTSSMRGCCDCGSTKLPYYEF
EKVHVQ
 ----+----1----+----2----+----3----+----4----+----5
Hydropathies  
 
Home   Imprint
© 2007-2017 Dr. Katja Kapp, Kassel & thpr.net e. K., Dresden, Germany, last update 2010-06-11